MY119375A - Treatment of tinnitus using neuroprotective agents - Google Patents

Treatment of tinnitus using neuroprotective agents

Info

Publication number
MY119375A
MY119375A MYPI96003783A MYPI9603783A MY119375A MY 119375 A MY119375 A MY 119375A MY PI96003783 A MYPI96003783 A MY PI96003783A MY PI9603783 A MYPI9603783 A MY PI9603783A MY 119375 A MY119375 A MY 119375A
Authority
MY
Malaysia
Prior art keywords
treatment
tinnitus
neuroprotective agents
mammal
compound
Prior art date
Application number
MYPI96003783A
Other languages
English (en)
Inventor
Steven B Sands
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MY119375A publication Critical patent/MY119375A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
MYPI96003783A 1995-09-15 1996-09-13 Treatment of tinnitus using neuroprotective agents MY119375A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US385595P 1995-09-15 1995-09-15

Publications (1)

Publication Number Publication Date
MY119375A true MY119375A (en) 2005-05-31

Family

ID=21707919

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI96003783A MY119375A (en) 1995-09-15 1996-09-13 Treatment of tinnitus using neuroprotective agents

Country Status (17)

Country Link
US (1) US5716961A (de)
EP (1) EP0768086B1 (de)
JP (1) JP3038155B2 (de)
KR (1) KR970014765A (de)
CN (1) CN1104892C (de)
AT (1) ATE224714T1 (de)
AU (1) AU697679B2 (de)
CA (1) CA2185512C (de)
DE (1) DE69623899T2 (de)
DK (1) DK0768086T3 (de)
ES (1) ES2181853T3 (de)
IL (1) IL119207A (de)
MY (1) MY119375A (de)
NZ (1) NZ299376A (de)
PT (1) PT768086E (de)
TW (1) TW450807B (de)
ZA (1) ZA967746B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
IL145451A0 (en) * 1999-04-07 2002-06-30 Pfizer Prod Inc Use of cyp2d6 inhibitors in combination therapies
US6586446B1 (en) 1999-10-15 2003-07-01 Bristol-Myers Squibb Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
US6784200B2 (en) * 2000-10-13 2004-08-31 Bristol-Myers Squibb Pharma Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
YU27801A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
SE0100344D0 (sv) * 2001-02-05 2001-02-05 Jan Nordmark New Use
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US7589110B2 (en) * 2002-09-06 2009-09-15 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
CA2620374C (en) * 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
WO2009033079A1 (en) * 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200924746A (en) * 2007-09-07 2009-06-16 Xenoport Inc Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
US8454877B2 (en) * 2009-04-03 2013-06-04 Pelican Products, Inc. Method and apparatus for molding an article
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
FI934566L (fi) * 1991-04-18 1993-10-15 Pfizer Prodrug-estrar av fenol-2-piperidino-1-alkanoler
EP0542689B1 (de) * 1991-11-15 1998-09-23 Phafag Aktiengesellschaft Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS 119:95538 (1992) *

Also Published As

Publication number Publication date
EP0768086B1 (de) 2002-09-25
CA2185512A1 (en) 1997-03-16
KR970014765A (ko) 1997-04-28
IL119207A0 (en) 1996-12-05
ATE224714T1 (de) 2002-10-15
DK0768086T3 (da) 2002-10-14
ZA967746B (en) 1998-03-13
EP0768086A1 (de) 1997-04-16
PT768086E (pt) 2003-01-31
MX9603819A (es) 1997-07-31
ES2181853T3 (es) 2003-03-01
IL119207A (en) 2004-05-12
JP3038155B2 (ja) 2000-05-08
CN1104892C (zh) 2003-04-09
DE69623899D1 (de) 2002-10-31
CA2185512C (en) 2000-08-08
JPH09124482A (ja) 1997-05-13
NZ299376A (en) 2000-07-28
CN1149454A (zh) 1997-05-14
DE69623899T2 (de) 2003-01-23
AU697679B2 (en) 1998-10-15
AU6563596A (en) 1997-03-20
US5716961A (en) 1998-02-10
TW450807B (en) 2001-08-21

Similar Documents

Publication Publication Date Title
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
CA2292359A1 (en) Novel azalides and methods of making same
PL310476A1 (en) Application of lamotrigin in treating neuro-aids diseases
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
PL333920A1 (en) 3-pyridyl enantiomers and their application as pain-relieving agents
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
BG105664A (en) Use of apomophines for the treatment of organic erectile dysfunction in males
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
PL342099A1 (en) Therapeutic agents
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
GB9907571D0 (en) Compounds
BR9304573A (pt) Compostos 2-alcoxi-2-imidazolin-5-onas, processo de preparaçao desses compostos, composiçoes fungicidas e processo de tratamento de culturas contra doenças fúngicas
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
MY104521A (en) Treatment of depression.
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
IL146962A0 (en) Aminotetralin derivatives for the therapy of cardiovascular diseases
MY133222A (en) Method of treating glaucoma and ischemic retinopathy
EP0872239A3 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
US6541495B1 (en) Carboxylic acid derivatives as inhibitors of hyperproliferation diseases
MX9605153A (es) Agentes farmaceuticos para el tratamiento de enfermedades inflamatorias cronicas y agudas.